Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

49 results about "Tissue microarray" patented technology

Tissue microarrays (also TMAs) consist of paraffin blocks in which up to 1000 separate tissue cores are assembled in array fashion to allow multiplex histological analysis.

Application of SMOC2 gene in preparation of medicine for detecting or treating endometrial cancer and ovarian cancer

The invention provides application of SMOC2 gene (SPARC related modular calcium binding2, with the Chinese name of secreting modular calcium binding protein 2; smooth muscle related protein 2) in preparation of medicine for detecting or treating endometrial cancer and ovarian cancer. A tissue chip comprising 157 endometrial cancer tissue specimens, 30 normal proliferative phase endometrium tissue specimens and 30 normal secretory phase endometrium tissue specimens is established by utilizing a tissue microarray technology, the expression conditions of SMOC2 in the specimens are detected by utilizing the immunohistochemical technique, the positive expression rate of the SMOC2 in the normal tissue of the endometrium is far lower than the positive expression rate in the endometrial cancer, and the expression intensity is positively correlated to muscular invasion depth of the endometrial cancer and tumor grading of the endometrial cancer. Therefore, the SMOC2 gene can be used for preparing the medicine for detecting or treating endometrial cancer. The medicine is reliable in experimental result and high in repeatability and has good clinical application prospect and good application values and social benefits.
Owner:FENGXIAN CENT HOSPITAL

HER2 image classification method and system based on convolution and residual networks

The invention discloses an HER2 image classification method and system based on convolution and a residual network. The method comprises the steps: obtaining a plurality of HER2 images with annotations from a tissue microarray database, and taking the HER2 images with annotations as an initial data sample; respectively cutting each initial data sample by adopting a cutting function, and establishing an extended data sample set; training the convolution and residual error network by using the extended data sample set to obtain a trained convolution and residual error network as an HER2 image classification model; and inputting the HER2 image to be classified into the HER2 image classification model to obtain a classification result of the HER2 image to be classified. According to the HER2 image classification method, more HER2 images are obtained by utilizing the clipping function, so that the technical defect that the data volume of the HER2 images cannot meet the training requirementis overcome. The HER2 image classification is realized by utilizing the convolution and residual network, the over-fitting phenomenon of an existing neural network model is avoided, and the HER2 imageclassification method is realized under the condition that the data volume is relatively small. The HER2 images are automatically and accurately classified by using the neural network model.
Owner:QILU UNIV OF TECH

Identification and use of prognostic and predictive markers in cancer treatment

The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. In addition, the present invention provides a method of treating breast cancer that includes measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP. The present invention also encompasses a method of treating breast cancer that includes screening a breast cancer patient for amplification of the cMYC gene and then treating a patient having amplification of the cMYC gene with therapeutic quantities of a compound that interferes with HER2 signaling.
Owner:NSABP FOUND INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products